Immunome, Inc. Profile Avatar - Palmy Investing

Immunome, Inc.

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoti…

Biotechnology
US, Exton [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Immunome, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of IMNM's Analysis
CIK: 1472012 CUSIP: 45257U108 ISIN: US45257U1088 LEI: - UEI: -
Secondary Listings
IMNM has no secondary listings inside our databases.